Royalty Pharma PLC (MEX:RPRX)
MXN 528.5 0 (0%) Market Cap: 243.55 Bil Enterprise Value: 363.97 Bil PE Ratio: 10.43 PB Ratio: 1.73 GF Score: 75/100

Royalty Pharma PLC at Citi BioPharma Conference Transcript

Sep 06, 2023 / 03:20PM GMT
Release Date Price: MXN530
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

So I think we're ready to start. Delighted to introduce the management from Royalty Pharma. And unusually, I've worked with both at two separate organizations during my career. So starting on the far left was my former counterpart at Citi, Chris Hite, who is now Vice Chairman of Royalty Pharma. And the gentlemen next to him, who I worked with when I was at another house, I won't mention, is Marshall Urist, who is the Head of Research and Investments at Royalty Pharma. So great to have you both here.

To the audience if you have got any questions that you'd like to ask, just raise a hand and if I'm not blinded by the light I will try and take them.

Questions & Answers

Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

So just maybe to start off, look, the obvious place to start is the share price right? And it is below the IPO, it's obviously, probably about half where it was at its highs. In terms of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot